middle.news
Avecho Advances Phase III Insomnia Trial with Positive Interim Analysis
9:43am on Wednesday 29th of July, 2026 AEST
•
Healthcare
Read Story
Avecho Advances Phase III Insomnia Trial with Positive Interim Analysis
9:43am on Wednesday 29th of July, 2026 AEST
Key Points
Independent Data Monitoring Board endorses continuation of Phase III trial at original size
No serious adverse events reported among 244 participants
Raised $1.9 million from option exercises simplifying capital structure
Received $1.98 million R&D tax incentive refund
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Avecho Biotechnology (ASX:AVE)
OPEN ARTICLE